Active Ingredient History
Reboxetine, sold under the brand name Edronax among others, is a drug of the norepinephrine reuptake inhibitor (NRI) class, marketed as an antidepressant by Pfizer for use in the treatment of major depression, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD). It is approved for use in many countries worldwide, but has not been approved for use in the United States. Although its effectiveness as an antidepressant has been challenged in multiple published reports, its popularity has continued to increase. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Abdominal Pain (Phase 4)
Amphetamine-Related Disorders (Phase 1)
Anxiety Disorders (Phase 3)
Bone Diseases (Phase 3)
Cataplexy (Phase 3)
Dementia (Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 2)
Disorders of Excessive Somnolence (Phase 3)
Fatigue (Phase 3)
Fecal Incontinence (Phase 1)
Mood Disorders (Phase 1)
Narcolepsy (Phase 3)
Pain (Phase 4)
Psychophysiologic Disorders (Phase 3)
Schizophrenia (Phase 4)
Sleep Apnea, Obstructive (Phase 2/Phase 3)
Sleep Disorders, Intrinsic (Phase 2)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Substance-Related Disorders (Phase 1)
Urinary Incontinence, Stress (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue